진행성 다소성 백질뇌증 치료 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2031년) - 약물 유형별, 적응증별, 유통 채널별, 지역별

Progressive Multifocal Leukoencephalopathy Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region:

US $ 4,995 ￦ 7,153,000

Unprintable PDF & Excel (Single User License)

PDF 및 Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 텍스트의 Copy&Paste도 불가능합니다.

US $ 8,495 ￦ 12,166,000

Unprintable PDF & Excel (Multi User License upto 5 users)

PDF 및 Excel 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 텍스트는 Copy & Paste 가능하지만, 인쇄는 불가능합니다.

US $ 10,600 ￦ 15,181,000

Printable PDF & Excel (Enterprise License above 5 users)

PDF 및 Excel 보고서를 동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용자수는 5명 이상이며 제한은 없습니다. Copy & Paste 및 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계 진행성 다소성 백질뇌증 치료 시장 규모는 2024년부터 2031년까지 꾸준한 성장세를 보일 것으로 예상됩니다. 많은 중저소득 국가에서 HIV 감염률이 증가함에 따라 진행성 다소성 백질뇌증 치료에 대한 수요가 증가할 것으로 예상됩니다. 혈액학적 악성 종양 발병률 증가와 진행성 다발성 백혈병성 뇌병증 진단이 시장 확대의 원동력이 되고 있으며, HIV 및 암 치료에 대한 우호적인 상환 정책이 진행성 다발성 백혈병성 뇌병증 치료제 시장의 성장을 촉진할 것으로 예상됩니다. 항레트로바이러스 및 항바이러스 요법을 포함한 새로운 치료 옵션의 도입은 시장 신규 진입자에게 유리한 기회를 제공하고 있으며, HIV 및 진행성 다발성 백혈병 뇌병증의 검사, 진단 및 치료의 발전은 의료 시설 및 정부 프로그램의 개선과 함께 시장 성장을 촉진하고 있습니다. 시장 성장을 견인하고 있습니다.

북미에 이어 유럽이 HIV 감염, 혈액 악성 종양, 진행성 다발성 백혈병 뇌병증의 유병률 증가에 힘입어 진행성 다발성 백혈병 치료제 시장을 주도할 것으로 예측됩니다. 아시아태평양 시장은 HIV 감염률 증가, HIV 및 암 치료율 향상, 진행성 다발성 백혈병 뇌병증에 대한 인식 개선으로 지속적인 성장이 예상됩니다. 중저소득 국가들의 치료율 증가, 안전하고 효과적인 치료 및 정확한 암 진단에 대한 접근성 증가는 진행성 다발성 백혈병 진단 증가에 기여할 것으로 보입니다.

이 보고서는 세계 진행성 다소성 백질뇌증 치료 시장을 조사했으며, 시장 개요와 함께 약제 종류별, 적응증별, 유통 채널별, 지역별 동향, 시장 진입 기업의 경쟁 동향 등을 전해드립니다.

목차

제1장 주요 요약

제2장 시장 개요

• 시장 정의와 세분화
• 시장 역학
• 밸류체인 분석
• Porter's Five Forces 분석
• COVID-19의 영향 분석
• 우크라이나와 러시아 분쟁의 영향
• 경제 개요
• PESTLE 분석

제3장 세계의 진행성 다소성 백질뇌증 치료 시장 전망, 2018-2031년

• 세계의 진행성 다소성 백질뇌증 치료 시장 전망, 약제 유형별, 금액(10억 달러), 2018-2031년
• 세계의 진행성 다소성 백질뇌증 치료 시장 전망, 적응증별, 금액(10억 달러), 2018-2031년
• 세계의 진행성 다소성 백질뇌증 치료 시장 전망, 유통 채널별, 금액(10억 달러), 2018-2031년
• 세계의 진행성 다소성 백질뇌증 치료 시장 전망, 지역별, 금액(10억 달러), 2018-2031년

제4장 북미의 진행성 다소성 백질뇌증 치료 시장 전망, 2018-2031년

제5장 유럽의 진행성 다소성 백질뇌증 치료 시장 전망, 2018-2031년

제6장 아시아태평양의 진행성 다소성 백질뇌증 치료 시장 전망, 2018-2031년

제7장 라틴아메리카의 진행성 다소성 백질뇌증 치료 시장 전망, 2018-2031년

제8장 중동 및 아프리카의 진행성 다소성 백질뇌증 치료 시장 전망, 2018-2031년

제9장 경쟁 상황

• 약제 유형과 유통 채널 히트맵
• 제조업체와 유통 채널 히트맵
• 기업의 시장 점유율 분석, 2023년
• 경쟁 대시보드
• 기업 개요
  • Pfizer, Inc.
  • F. Hoffman - La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Sanofi S.A.
  • Allergan plc
  • Novartis AG
  • Mylan N.V.
  • AbbVie Inc.
  • Bristol-Myers Squibb Company

제10장 부록

ksm

영문 목차

영문목차

The global progressive multifocal leukoencephalopathy treatment market is set to experience steady growth from 2024 to 2031. Several key insights are driving this growth in the market:

Factors Driving Market Growth:

• Rising HIV Prevalence: The growing prevalence of HIV infection in many middle- and low-income countries is expected to fuel the demand for progressive multifocal leukoencephalopathy treatment.
• Hematological Malignancies: An increasing incidence of hematological malignancies and the diagnosis of progressive multifocal leukoencephalopathy are driving the market's expansion.
• Favorable Reimbursements: Favorable reimbursement policies for HIV and cancer treatments are expected to stimulate growth in the progressive multifocal leukoencephalopathy treatment market.
• Emerging Treatment Options: The introduction of emerging treatment options, including anti-retroviral and antiviral therapies, is creating lucrative opportunities for new entrants in the market.
• Healthcare Infrastructure Improvement: Advances in HIV and progressive multifocal leukoencephalopathy testing, diagnosis, and treatment, along with improved healthcare facilities and government programs, are boosting market growth.

Regional Outlook:

• North America: North America, followed by Europe, is anticipated to lead the progressive multifocal leukoencephalopathy treatment market, driven by the increasing prevalence of HIV infection, hematological malignancies, and progressive multifocal leukoencephalopathy.
• Asia-Pacific: The Asia-Pacific market is expected to witness continuous growth due to the rising HIV infection rates, improving treatment rates for HIV and cancer, and increasing awareness about progressive multifocal leukoencephalopathy.
• Middle East & Africa: Growing treatment-seeking rates in middle- and low-income economies, along with access to safe and effective treatment and accurate cancer diagnosis, will likely contribute to increased progressive multifocal leukoencephalopathy diagnoses.

Opportunities for Growth:

• Antiviral Agents: The use of antiviral agents, immune response modulators, and immunization treatment for potential progressive multifocal leukoencephalopathy patients is expected to drive market growth.
• Research and Development: Emphasis on researching and developing drugs and therapies for rare diseases presents a significant opportunity for the progressive multifocal leukoencephalopathy treatment market.
• Innovative Therapies: Companies are exploring innovative therapies to control JC virus infection rather than improving immunity, which is likely to spur market growth.
• Improvement in Available Treatments: Leading companies in the progressive multifocal leukoencephalopathy treatment market are focusing on enhancing available treatment options.

Key Players:

Some of the key players in the global progressive multifocal leukoencephalopathy treatment market include Pfizer, Inc., GlaxoSmithKline Plc, Sanofi S.A., Gilead Sciences, Inc., Allergan Plc. (Actavis Plc.), Novartis AG, F. Hoffman - La Roche Ltd., AbbVie Inc., and Bristol-Myers Squibb Company, among others.

Table of Contents

1. Executive Summary

• 1.1. Global Progressive Multifocal Leukoencephalopathy Treatment Market Snapshot
• 1.2. Future Projections
• 1.3. Key Market Trends
• 1.4. Regional Snapshot, by Value, 2023
• 1.5. Analyst Recommendations

2. Market Overview

• 2.1. Market Definitions and Segmentations
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Market Opportunities
• 2.3. Value Chain Analysis
• 2.4. Porter's Five Forces Analysis
• 2.5. COVID-19 Impact Analysis
  • 2.5.1. Supply
  • 2.5.2. Demand
• 2.6. Impact of Ukraine-Russia Conflict
• 2.7. Economic Overview
  • 2.7.1. World Economic Projections
• 2.8. PESTLE Analysis

3. Global Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, 2018 - 2031

• 3.1. Global Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
  • 3.1.1. Key Highlights
    • 3.1.1.1. Anti-retroviral Therapy
    • 3.1.1.2. Antiviral/Anti JCV
    • 3.1.1.3. Other Symptomatic
• 3.2. Global Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
  • 3.2.1. Key Highlights
    • 3.2.1.1. HIV/AIDS
    • 3.2.1.2. Organ Transplantation
    • 3.2.1.3. Multiple Sclerosis
    • 3.2.1.4. Hematological Malignancies
• 3.3. Global Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 3.3.1. Key Highlights
    • 3.3.1.1. Hospital Pharmacies
    • 3.3.1.2. Drug Stores
    • 3.3.1.3. Retail Pharmacies
• 3.4. Global Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
  • 3.4.1. Key Highlights
    • 3.4.1.1. North America
    • 3.4.1.2. Europe
    • 3.4.1.3. Asia Pacific
    • 3.4.1.4. Latin America
    • 3.4.1.5. Middle East & Africa

4. North America Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, 2018 - 2031

• 4.1. North America Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
  • 4.1.1. Key Highlights
    • 4.1.1.1. Anti-retroviral Therapy
    • 4.1.1.2. Antiviral/Anti JCV
    • 4.1.1.3. Other Symptomatic
• 4.2. North America Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
  • 4.2.1. Key Highlights
    • 4.2.1.1. HIV/AIDS
    • 4.2.1.2. Organ Transplantation
    • 4.2.1.3. Multiple Sclerosis
    • 4.2.1.4. Hematological Malignancies
• 4.3. North America Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 4.3.1. Key Highlights
    • 4.3.1.1. Hospital Pharmacies
    • 4.3.1.2. Drug Stores
    • 4.3.1.3. Retail Pharmacies
• 4.4. North America Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
  • 4.4.1. Key Highlights
    • 4.4.1.1. U.S. Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
    • 4.4.1.2. U.S. Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
    • 4.4.1.3. U.S. Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 4.4.1.4. Canada Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
    • 4.4.1.5. Canada Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
    • 4.4.1.6. Canada Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 4.4.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, 2018 - 2031

• 5.1. Europe Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
  • 5.1.1. Key Highlights
    • 5.1.1.1. Anti-retroviral Therapy
    • 5.1.1.2. Antiviral/Anti JCV
    • 5.1.1.3. Other Symptomatic
• 5.2. Europe Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
  • 5.2.1. Key Highlights
    • 5.2.1.1. HIV/AIDS
    • 5.2.1.2. Organ Transplantation
    • 5.2.1.3. Multiple Sclerosis
    • 5.2.1.4. Hematological Malignancies
• 5.3. Europe Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 5.3.1. Key Highlights
    • 5.3.1.1. Hospital Pharmacies
    • 5.3.1.2. Drug Stores
    • 5.3.1.3. Retail Pharmacies
• 5.4. Europe Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
  • 5.4.1. Key Highlights
    • 5.4.1.1. Germany Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
    • 5.4.1.2. Germany Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
    • 5.4.1.3. Germany Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.4.1.4. U.K. Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
    • 5.4.1.5. U.K. Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
    • 5.4.1.6. U.K. Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.4.1.7. France Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
    • 5.4.1.8. France Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
    • 5.4.1.9. France Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.4.1.10. Italy Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
    • 5.4.1.11. Italy Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
    • 5.4.1.12. Italy Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.4.1.13. Turkey Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
    • 5.4.1.14. Turkey Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
    • 5.4.1.15. Turkey Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.4.1.16. Russia Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
    • 5.4.1.17. Russia Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
    • 5.4.1.18. Russia Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.4.1.19. Rest of Europe Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
    • 5.4.1.20. Rest of Europe Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
    • 5.4.1.21. Rest of Europe Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 5.4.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, 2018 - 2031

• 6.1. Asia Pacific Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
  • 6.1.1. Key Highlights
    • 6.1.1.1. Anti-retroviral Therapy
    • 6.1.1.2. Antiviral/Anti JCV
    • 6.1.1.3. Other Symptomatic
• 6.2. Asia Pacific Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
  • 6.2.1. Key Highlights
    • 6.2.1.1. HIV/AIDS
    • 6.2.1.2. Organ Transplantation
    • 6.2.1.3. Multiple Sclerosis
    • 6.2.1.4. Hematological Malignancies
• 6.3. Asia Pacific Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 6.3.1. Key Highlights
    • 6.3.1.1. Hospital Pharmacies
    • 6.3.1.2. Drug Stores
    • 6.3.1.3. Retail Pharmacies
• 6.4. Asia Pacific Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
  • 6.4.1. Key Highlights
    • 6.4.1.1. China Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
    • 6.4.1.2. China Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
    • 6.4.1.3. China Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.4.1.4. Japan Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
    • 6.4.1.5. Japan Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
    • 6.4.1.6. Japan Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.4.1.7. South Korea Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
    • 6.4.1.8. South Korea Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
    • 6.4.1.9. South Korea Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.4.1.10. India Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
    • 6.4.1.11. India Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
    • 6.4.1.12. India Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.4.1.13. Southeast Asia Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
    • 6.4.1.14. Southeast Asia Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
    • 6.4.1.15. Southeast Asia Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.4.1.16. Rest of Asia Pacific Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
    • 6.4.1.17. Rest of Asia Pacific Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
    • 6.4.1.18. Rest of Asia Pacific Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, 2018 - 2031

• 7.1. Latin America Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
  • 7.1.1. Key Highlights
    • 7.1.1.1. Anti-retroviral Therapy
    • 7.1.1.2. Antiviral/Anti JCV
    • 7.1.1.3. Other Symptomatic
• 7.2. Latin America Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
  • 7.2.1. Key Highlights
    • 7.2.1.1. HIV/AIDS
    • 7.2.1.2. Organ Transplantation
    • 7.2.1.3. Multiple Sclerosis
    • 7.2.1.4. Hematological Malignancies
• 7.3. Latin America Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 7.3.1. Key Highlights
    • 7.3.1.1. Hospital Pharmacies
    • 7.3.1.2. Drug Stores
    • 7.3.1.3. Retail Pharmacies
• 7.4. Latin America Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
  • 7.4.1. Key Highlights
    • 7.4.1.1. Brazil Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
    • 7.4.1.2. Brazil Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
    • 7.4.1.3. Brazil Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.4.1.4. Mexico Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
    • 7.4.1.5. Mexico Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
    • 7.4.1.6. Mexico Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.4.1.7. Argentina Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
    • 7.4.1.8. Argentina Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
    • 7.4.1.9. Argentina Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.4.1.10. Rest of Latin America Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
    • 7.4.1.11. Rest of Latin America Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
    • 7.4.1.12. Rest of Latin America Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, 2018 - 2031

• 8.1. Middle East & Africa Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
  • 8.1.1. Key Highlights
    • 8.1.1.1. Anti-retroviral Therapy
    • 8.1.1.2. Antiviral/Anti JCV
    • 8.1.1.3. Other Symptomatic
• 8.2. Middle East & Africa Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
  • 8.2.1. Key Highlights
    • 8.2.1.1. HIV/AIDS
    • 8.2.1.2. Organ Transplantation
    • 8.2.1.3. Multiple Sclerosis
    • 8.2.1.4. Hematological Malignancies
• 8.3. Middle East & Africa Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 8.3.1. Key Highlights
    • 8.3.1.1. Hospital Pharmacies
    • 8.3.1.2. Drug Stores
    • 8.3.1.3. Retail Pharmacies
• 8.4. Middle East & Africa Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
  • 8.4.1. Key Highlights
    • 8.4.1.1. GCC Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
    • 8.4.1.2. GCC Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
    • 8.4.1.3. GCC Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.4.1.4. South Africa Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
    • 8.4.1.5. South Africa Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
    • 8.4.1.6. South Africa Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.4.1.7. Egypt Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
    • 8.4.1.8. Egypt Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
    • 8.4.1.9. Egypt Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.4.1.10. Nigeria Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
    • 8.4.1.11. Nigeria Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
    • 8.4.1.12. Nigeria Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.4.1.13. Rest of Middle East & Africa Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
    • 8.4.1.14. Rest of Middle East & Africa Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
    • 8.4.1.15. Rest of Middle East & Africa Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

• 9.1. Drug Type vs Distribution Channel Heatmap
• 9.2. Manufacturer vs Distribution Channel Heatmap
• 9.3. Company Market Share Analysis, 2023
• 9.4. Competitive Dashboard
• 9.5. Company Profiles
  • 9.5.1. Pfizer, Inc.
    • 9.5.1.1. Company Overview
    • 9.5.1.2. Drug Type Portfolio
    • 9.5.1.3. Financial Overview
    • 9.5.1.4. Business Strategies and Development
  • 9.5.2. F. Hoffman - La Roche Ltd.
    • 9.5.2.1. Company Overview
    • 9.5.2.2. Drug Type Portfolio
    • 9.5.2.3. Financial Overview
    • 9.5.2.4. Business Strategies and Development
  • 9.5.3. Gilead Sciences, Inc.
    • 9.5.3.1. Company Overview
    • 9.5.3.2. Drug Type Portfolio
    • 9.5.3.3. Financial Overview
    • 9.5.3.4. Business Strategies and Development
  • 9.5.4. GlaxoSmithKline plc
    • 9.5.4.1. Company Overview
    • 9.5.4.2. Drug Type Portfolio
    • 9.5.4.3. Financial Overview
    • 9.5.4.4. Business Strategies and Development
  • 9.5.5. Sanofi S.A.
    • 9.5.5.1. Company Overview
    • 9.5.5.2. Drug Type Portfolio
    • 9.5.5.3. Financial Overview
    • 9.5.5.4. Business Strategies and Development
  • 9.5.6. Allergan plc
    • 9.5.6.1. Company Overview
    • 9.5.6.2. Drug Type Portfolio
    • 9.5.6.3. Financial Overview
    • 9.5.6.4. Business Strategies and Development
  • 9.5.7. Novartis AG
    • 9.5.7.1. Company Overview
    • 9.5.7.2. Drug Type Portfolio
    • 9.5.7.3. Financial Overview
    • 9.5.7.4. Business Strategies and Development
  • 9.5.8. Mylan N.V.
    • 9.5.8.1. Company Overview
    • 9.5.8.2. Drug Type Portfolio
    • 9.5.8.3. Financial Overview
    • 9.5.8.4. Business Strategies and Development
  • 9.5.9. AbbVie Inc.
    • 9.5.9.1. Company Overview
    • 9.5.9.2. Drug Type Portfolio
    • 9.5.9.3. Financial Overview
    • 9.5.9.4. Business Strategies and Development
  • 9.5.10. Bristol-Myers Squibb Company
    • 9.5.10.1. Company Overview
    • 9.5.10.2. Drug Type Portfolio
    • 9.5.10.3. Financial Overview
    • 9.5.10.4. Business Strategies and Development

10. Appendix

• 10.1. Research Methodology
• 10.2. Report Assumptions
• 10.3. Acronyms and Abbreviations

관련자료